COVID-19 patients He was admitted to the intensive care unit for the novel coronavirus (COVID-19) (ICU) of the Clinic “Clinic Darmstadt” in Darmstadt. Germany, 20 May 2021
Kai Faffenbach | Reuters
London — UK study results Low-cost, over-the-counter aspirin has been found to not improve survival in hospitalized patients with COVID-19.
Oxford University researchers hope to find that blood-thinning drugs can help COVID-19 patients. admitted to hospital which has an increased risk of developing blood clots in the blood vessels especially in the lungs But aspirin did not prevent death.
The study, which is part of a broader “recovery” trial that examines various possible treatments. For those hospitalized with coronavirus, nearly 15,000 people are hospitalized with the virus. About half of the patients received 150 mg of aspirin per day, compared with half who received usual care alone.
The study found “There was no evidence that aspirin treatment reduced mortality” and “no significant difference” in the number of deaths, with 17% of people in both groups dying in hospital after 28 days.
“The data show that in patients hospitalized with Covid-19, aspirin was not associated with a reduction in 28-day mortality or in risk of progressing to ventilator use or death,” said Peter Horby, professor of emerging infectious diseases in the Nuffield Department of Medicine at the University of Oxford. and co-lead investigator for the RECOVERY trial describes the study.
“Although aspirin is associated with the possibility of being released in spite of with a slight increase But it seems insufficient to justify its widespread use for hospitalized patients with COVID-19.”
Martin Landray, professor of medicine and epidemiology at the Nuffield Department of Population Health at the University of Oxford and one of the lead researchers on the study. Describing the results as “disappointing”
“There is strong suggestion that blood clotting can impair lung function and death in severe COVID-19 patients. Aspirin is inexpensive and widely used in other diseases to reduce risk. of thrombosis, so it’s disappointing to do There were no major effects for these patients. For this reason, large-scale randomized trials are very important – to determine which treatments work and which do not.”
The RECOVERY trial has made several life-saving discoveries. One is dexamethasone. which is a cheap and widely used steroid Can save lives of COVID-19 patients seriously ill
The results of the latest study on aspirin will be published shortly on the medRxiv pre-print website and sent to leading peer-reviewed medical journals.